Journal article
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)–5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non–ST-segment elevation acute coronary syndromes
Abstract
BACKGROUND: Factor Xa plays a central role in the generation of thrombin, making it a novel target for treatment of arterial thrombosis. Fondaparinux, a synthetic pentasaccharide, is a factor Xa inhibitor, which has been shown to be superior to enoxaparin for the prevention of venous thrombosis. We designed a large, phase III, randomized trial to evaluate the efficacy and safety of fondaparinux compared with enoxaparin in acute coronary …
Authors
Mehta SR; Yusuf S; Granger CB; Wallentin L; Peters RJG; Bassand J-P; Budaj A; Joyner C; Chrolavicius S; Fox KAA
Journal
American Heart Journal, Vol. 150, No. 6, pp. 1107.e1–1107.e10
Publisher
Elsevier
Publication Date
12 2005
DOI
10.1016/j.ahj.2005.09.025
ISSN
0002-8703